Home » Novo Nordisk Hikes 2026 Outlook Again

Novo Nordisk Hikes 2026 Outlook Again

November 4, 2026November 4, 2026

This post was originally published on this site.

The Ozempic maker raised its full-year outlook for the third time this year on Wednesday as its Wegovy pill beat third-quarter sales forecasts, boosting the Danish firm’s bid to win back ground from US rival Eli Lilly.

FlashNews:

SMUD Rebates Up to $3,000 for Heat Pumps and Heating Systems Before Winter

GoodsQC Introduces Structured Product Sourcing Workflow to Support Overseas Buyers Shopping on Chinese Marketplaces

Wyndham Unveils Asia Pacific New Year Offers

Nasdaq tumbles as chip rout intensifies after midterms

European stocks overtake Wall Street following Democratic sweep

AI backlash threatens trillion-dollar data centre boom, say tech leaders

Finding New Drugs Is Laborious. This AI Startup Is Skipping The Lab Work

Motorola Wants to Sell You a $1,600 Phone That Doesn’t Fold

Fashion Label Guizio Launches Perfume

Tapestry Lifts Outlook as Young Shoppers Snap Up Coach Bags

Trump’s memecoin ventures derailed CLARITY Act, Scaramucci says

Married at First Sight UK cancelled after BBC revealed rape allegations

Stone to be laid for Mobo founder Kanya King

AI’s Next Trick? Speaking Dolphin

Best Wireless Chargers (2026): My Picks After Testing 100+

He Trolls AI Labs for a Living. Now They All Want to Work With Him

VIVA Cruises announces new name for Douro ship

Thailand to block Bitget in December over unlicensed crypto trading

Air India hosts UK travel trade leaders in London with Hon’ble Minister of Tourism and Culture

The Pitt and ER are similar enough for lawsuit to proceed, judge rules

Novo Nordisk Hikes 2026 Outlook Again